Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
17 November 2023 - 9:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2023.
Commission File Number: 001-39530
ImmunoPrecise Antibodies Ltd.
(Exact Name of Registrant as Specified in Charter)
3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠
INCORPORATION BY REFERENCE
Exhibit 99.1 of this Form 6-K is incorporated by reference into the Registrant's Registration Statement on Form F-3 (File No. 333-273197) and Registration Statement on Form S-8 (File No. 333-256730).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
IMMUNOPRECISE ANTIBODIES LTD. |
|
|
|
|
Date: |
November 16, 2023 |
By: |
/s/ Kristin Taylor
|
|
|
Name: |
Kristin Taylor |
|
|
Title: |
Chief Financial Officer |
EXHIBIT INDEX
Report of Voting Results
Submitted Pursuant to
Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations
In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of ImmunoPrecise Antibodies Ltd. (the "Corporation") held on November 9, 2023, via live webcast (the "Meeting"). Each of the matters is described in greater detail in the Corporation's management information circular dated October 16, 2023 (the "Circular").
(a) The number of directors was set at five. The following are the voting results on this matter:
|
FOR
|
% FOR
|
AGAINST
|
% AGAINST
|
Number of Directors
|
8,516,846
|
93.29%
|
612,909
|
6.71%
|
(b) In the Circular, management of the Corporation proposed five nominees for election as directors of the Corporation for the ensuing year or until their successors are duly elected or appointed. All five nominees were elected. The following are the voting results on this matter:
|
FOR |
% FOR |
WITHHELD
|
% WITHHELD |
Jennifer L. Bath |
6,985,276 |
94.46% |
409,710 |
5.54% |
Chris Buyse |
7,325,144 |
99.06% |
69,842 |
0.94% |
Mitch Levine |
7,324,705 |
99.05% |
70,281 |
0.95% |
Barry A. Springer |
7,324,876 |
99.05% |
70,110 |
0.95% |
Dirk Witters |
7,335,209 |
99.19% |
59,777 |
0.81% |
(c) Grant Thornton LLP was reappointed as the Corporation's auditors and the directors were authorized to fix the remuneration to be paid to the auditors. The following are the voting results on this matter:
|
FOR |
% FOR |
WITHHELD
|
% WITHHELD |
Reappointment of Auditors |
8,974,183 |
98.30% |
155,573 |
1.70% |
Dated this 16th day of November 2023.
|
IMMUNOPRECISE ANTIBODIES LTD. |
|
|
|
|
By: |
(signed) Kristin Taylor |
|
|
Name: Kristin Taylor |
|
|
Title: Chief Financial Officer |
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From May 2023 to May 2024